BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 32078015)

  • 1. Development and characterization of a novel anti-OX40 antibody for potent immune activation.
    Kuang Z; Jing H; Wu Z; Wang J; Li Y; Ni H; Zhang P; Wu W; Wu M; Zhou S; Qiu X; Wu D; Prinz B; Baruah H; Chen B; Yu M; Liu J
    Cancer Immunol Immunother; 2020 Jun; 69(6):939-950. PubMed ID: 32078015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.
    Kvarnhammar AM; Veitonmäki N; Hägerbrand K; Dahlman A; Smith KE; Fritzell S; von Schantz L; Thagesson M; Werchau D; Smedenfors K; Johansson M; Rosén A; Åberg I; Winnerstam M; Nyblom E; Barchan K; Furebring C; Norlén P; Ellmark P
    J Immunother Cancer; 2019 Apr; 7(1):103. PubMed ID: 30975201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models.
    Jiang B; Zhang T; Deng M; Jin W; Hong Y; Chen X; Chen X; Wang J; Hou H; Gao Y; Gong W; Wang X; Li H; Zhou X; Feng Y; Zhang B; Jiang B; Lu X; Zhang L; Li Y; Song W; Sun H; Wang Z; Song X; Shen Z; Liu X; Li K; Wang L; Liu Y
    Front Med; 2023 Dec; 17(6):1170-1185. PubMed ID: 37747585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligand-Blocking and Membrane-Proximal Domain Targeting Anti-OX40 Antibodies Mediate Potent T Cell-Stimulatory and Anti-Tumor Activity.
    Zhang P; Tu GH; Wei J; Santiago P; Larrabee LR; Liao-Chan S; Mistry T; Chu ML; Sai T; Lindquist K; Long H; Chaparro-Riggers J; Salek-Ardakani S; Yeung YA
    Cell Rep; 2019 Jun; 27(11):3117-3123.e5. PubMed ID: 31189099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale for anti-OX40 cancer immunotherapy.
    Aspeslagh S; Postel-Vinay S; Rusakiewicz S; Soria JC; Zitvogel L; Marabelle A
    Eur J Cancer; 2016 Jan; 52():50-66. PubMed ID: 26645943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PLGA-nanoparticle mediated delivery of anti-OX40 monoclonal antibody enhances anti-tumor cytotoxic T cell responses.
    Chen M; Ouyang H; Zhou S; Li J; Ye Y
    Cell Immunol; 2014 Feb; 287(2):91-9. PubMed ID: 24487032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells.
    Campos Carrascosa L; van Beek AA; de Ruiter V; Doukas M; Wei J; Fisher TS; Ching K; Yang W; van Loon K; Boor PPC; Rakké YS; Noordam L; Doornebosch P; Grünhagen D; Verhoef K; Polak WG; IJzermans JNM; Ni I; Yeung YA; Salek-Ardakani S; Sprengers D; Kwekkeboom J
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement.
    Gaspar M; Pravin J; Rodrigues L; Uhlenbroich S; Everett KL; Wollerton F; Morrow M; Tuna M; Brewis N
    Cancer Immunol Res; 2020 Jun; 8(6):781-793. PubMed ID: 32273279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis.
    Garrison K; Hahn T; Lee WC; Ling LE; Weinberg AD; Akporiaye ET
    Cancer Immunol Immunother; 2012 Apr; 61(4):511-21. PubMed ID: 21971588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
    Redmond WL; Linch SN; Kasiewicz MJ
    Cancer Immunol Res; 2014 Feb; 2(2):142-53. PubMed ID: 24778278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BAT6026, a novel anti-OX40 antibody with enhanced antibody dependent cellular cytotoxicity effect for cancer immunotherapy.
    Liang S; Zheng D; Liu X; Mei X; Zhou C; Xiao C; Qin C; Yue H; Lin J; Liu C; Li S; Yu JC
    Front Oncol; 2023; 13():1211759. PubMed ID: 37576888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing the Generation of Eomes
    Emerson DA; Rolig AS; Redmond WL
    Cancer Immunol Res; 2021 Apr; 9(4):430-440. PubMed ID: 33593794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
    Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA
    Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348
    [No Abstract]   [Full Text] [Related]  

  • 14. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.
    Guo Z; Wang X; Cheng D; Xia Z; Luan M; Zhang S
    PLoS One; 2014; 9(2):e89350. PubMed ID: 24586709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomimetic nanoparticles deliver mRNAs encoding costimulatory receptors and enhance T cell mediated cancer immunotherapy.
    Li W; Zhang X; Zhang C; Yan J; Hou X; Du S; Zeng C; Zhao W; Deng B; McComb DW; Zhang Y; Kang DD; Li J; Carson WE; Dong Y
    Nat Commun; 2021 Dec; 12(1):7264. PubMed ID: 34907171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression.
    Hebb JPO; Mosley AR; Vences-Catalán F; Rajasekaran N; Rosén A; Ellmark P; Felsher DW
    Cancer Immunol Immunother; 2018 Jan; 67(1):47-60. PubMed ID: 28905118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8
    Peng W; Williams LJ; Xu C; Melendez B; McKenzie JA; Chen Y; Jackson HL; Voo KS; Mbofung RM; Leahey SE; Wang J; Lizee G; Tawbi HA; Davies MA; Hoos A; Smothers J; Srinivasan R; Paul EM; Yanamandra N; Hwu P
    Clin Cancer Res; 2019 Nov; 25(21):6406-6416. PubMed ID: 31371342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second- and third-generation drugs for immuno-oncology treatment-The more the better?
    Dempke WCM; Fenchel K; Uciechowski P; Dale SP
    Eur J Cancer; 2017 Mar; 74():55-72. PubMed ID: 28335888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation and characterization of a high-affinity chimeric anti-OX40 antibody with potent antitumor activity.
    Yang Y; Chai X; Xin W; Wang D; Dai C; Qian F; Yang T
    FEBS Lett; 2021 Jun; 595(11):1587-1603. PubMed ID: 33792041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy.
    Fromm G; de Silva S; Johannes K; Patel A; Hornblower JC; Schreiber TH
    J Immunother Cancer; 2018 Dec; 6(1):149. PubMed ID: 30563566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.